PCML
UNCY icon

Pavaki Capital Management LLC’s Unicycive Therapeutics UNCY Stock Holding History

Pavaki Capital Management LLC’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-90,000
Closed -$519K – 162
2025
Q4 		$519K Buy
+90,000
New +$480K 0.2% 65

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pavaki Capital Management LLC's UNCY Position: Q1 2026 in Review

Pavaki Capital Management LLC sold out of Unicycive Therapeutics (UNCY) in Q1 2026, closing a stake of 90,000 shares — an estimated $519K sold.

Pavaki Capital Management LLC first reported a position in UNCY in Q4 2025 and held it in 1 quarter. The position peaked at $519K in Q4 2025. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Pavaki Capital Management LLC reported no remaining Unicycive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Pavaki Capital Management LLC sold 90,000 Unicycive Therapeutics shares in Q1 2026, an estimated $519K.
  • Pavaki Capital Management LLC first reported a position in Unicycive Therapeutics in Q4 2025 and held it in 1 quarter.
  • Pavaki Capital Management LLC's Unicycive Therapeutics position peaked at $519K in Q4 2025.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q1 2026, filed 7 Aug 2026.